Case report demonstrates successful treatment of idiopathic recurrent pericarditis using interleukin-1 inhibitors, highlighting the autoinflammatory pathway involved.
Key Points
Idiopathic recurrent pericarditis (IRP) appears to be an autoinflammatory disease driven by innate immune system dysregulation.
Histological evidence reveals critical support for autoinflammation in IRP pathogenesis, and the efficacy of interleukin-1 inhibitors is notable.
The case presented shows effective treatment of IRP with goflicicept, illustrating a hopeful treatment avenue for patients.
Patients with recurrent pericarditis may share familial patterns observed in other autoinflammatory diseases, such as familial Mediterranean fever.